OncoMatch/Clinical Trials/NCT05977998
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Is NCT05977998 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paclitaxel and Dexamethasone for gastric adenocarcinoma.
Treatment: Paclitaxel · Dexamethasone · Diphenhydramine · Famotidine — To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic cytotoxic chemotherapy — preoperative
Completion of preoperative systemic cytotoxic chemotherapy
Lab requirements
Blood counts
Leukocytes 3,000/uL; Absolute neutrophil count 1,500/uL; Platelets 6,000/uL
Kidney function
Serum creatinine 1.6 mg/dL
Adequate renal, and bone marrow function: Leukocytes 3,000/uL; Absolute neutrophil count 1,500/uL; Platelets 6,000/uL; Serum creatinine 1.6 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify